Effect of Cabergoline on Weight and Glucose Tolerance

Columbia University40 enrolled

Overview

The aim of this study is to determine the efficacy of cabergoline, a long-acting dopamine receptor agonist, on body weight and blood glucose in healthy obese adults. This is a randomized double-blind placebo controlled study. Twenty subjects each will be randomly assigned either placebo or cabergoline for 16 weeks. The effect of treatment on body weight and blood glucose and insulin levels will be compared in the treatment versus the placebo arm.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Masking

DOUBLE

Enrollment

Conditions

Body Weight Impaired Glucose Tolerance in Obese

Interventions

CabergolineDRUG

cabergoline 0.5 mg twice weekly

placeboOTHER

1 pill twice weekly

Eligibility

Sex: ALLMin age: 18 YearsMax age: 55 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * age 18 - 55 years * BMI 30 -40 Exclusion Criteria: * diabetes, * clinically significant medical condition, * use of medications that effect blood glucose or body weight

Locations (1)

Columbia University

New York, New York, United States

Outcomes

Primary Outcomes

body weight

Time frame: 16 weeks

Secondary Outcomes

glucose

Time frame: 16 weeks

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.